Inflexion acquires Irish CMO SteriPack

The GP will deploy equity from Buyout Fund VI, which closed at GBP 2.5bn in March 2022 and invests in European companies with an enterprise value up to GBP 1bn. 

The company provides outsourced design, development, manufacturing, assembly, packaging, sterilisation, and supply chain services for medical device, diagnostic and pharmaceutical businesses.

Inflexion said its funding will support the business to scale globally following recent acqusitions in the US. It already has facilities in Ireland, Poland and Malaysia. 

American private equity firm Great Point Partners had been a minority shareholder since 2019 following a growth capital injection, as reported. 

Great Point Partners invests USD 7m to USD 50m in companies that generate USD 10m to USD 100m in revenue and USD 2m to to USD 12m in EBITDA.

The deal marks another foray into healthcare for Inflexion, after the sponsor recently acquired CDMO Upperton via its Enterprise Fund V, which writes tickets of GBP 10m-GBP 75m in the UK lower-mid market. 

The GP's other healthcare investments include Rosemont Pharmaceuticals, a British liquid medicine manufacturer, which it carved out from listed US company Perrigo in June 2020 for GBP 156m.

It also carved out CNX Therapeutics in August 2021 from Sunovion; owns a minority stake in vaccination provider ELCG; and a majority stake in scientific data disseminator Pharmaspectra. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Buyouts
• UK / Ireland
• Inflexion Private Equity
• Ireland